Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 9.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,365,245 shares of the company’s stock after purchasing an additional 278,466 shares during the quarter. JPMorgan Chase & Co. owned 2.36% of Dyne Therapeutics worth $42,570,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of DYN. Chung Wu Investment Group LLC purchased a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after buying an additional 1,109 shares during the period. Ameritas Investment Partners Inc. raised its position in Dyne Therapeutics by 11.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after buying an additional 955 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after acquiring an additional 7,697 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in shares of Dyne Therapeutics in the 2nd quarter worth $111,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 1.3%

NASDAQ:DYN opened at $17.56 on Friday. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $25.00. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $16.96 and a 200-day simple moving average of $17.45. The company has a market capitalization of $2.90 billion, a PE ratio of -4.96 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

DYN has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 28th. Morgan Stanley reduced their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $36.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Brian S. Posner purchased 3,000 shares of the stock in a transaction dated Friday, March 6th. The shares were acquired at an average cost of $15.06 per share, for a total transaction of $45,180.00. Following the completion of the transaction, the director directly owned 11,500 shares of the company’s stock, valued at $173,190. This trade represents a 35.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 14.14% of the stock is owned by corporate insiders.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.